Chemotherapy Research Today is a free monthly online journal that collates and summarizes the latest research about Chemotherapy, including details on cancer treatment, side effects, drugs.

Volume 7 (2010), Issue 1 (January)

1. Does the anteromedial or anterolateral approach alter the rate of joint puncture in injection of the ankle?: A cadaver study.
   J Bone Joint Surg Br, 92(1): 176-8. [Abstract] [Full-text]
2. Cisplatin and etoposide chemotherapy combined with early concurrent twice-daily thoracic radiotherapy for limited-disease small cell lung cancer in elderly patients.
   Jpn J Clin Oncol, 40(1): 54-9. [Abstract] [Full-text]
3. A phase III trial of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in stage IVB, persistent or recurrent cervical cancer: Gynecologic Cancer Study Group/Japan Clinical Oncology Group Study (JCOG0505).
   Jpn J Clin Oncol, 40(1): 90-3. [Abstract] [Full-text]
4. A phase II study of irinotecan and capecitabine for patients with unresectable liver-only metastases from colorectal cancer.
   Jpn J Clin Oncol, 40(1): 10-6. [Abstract] [Full-text]
5. Phase II trial of gemcitabine combined with 5-fluorouracil and cisplatin (GFP) chemotherapy in patients with advanced biliary tree cancers.
   Jpn J Clin Oncol, 40(1): 24-8. [Abstract] [Full-text]
6. Symptomatic ectopic bone formation after off-label use of recombinant human bone morphogenetic protein-2 in transforaminal lumbar interbody fusion.
   J Neurosurg Spine, 12(1): 40-6. [Abstract] [Full-text]
7. Rapamycin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and induction of apoptosis.
   Int J Cancer, 126(5): 1144-54. [Abstract] [Full-text]
8. Sensitization of ovarian carcinoma cells to the atypical retinoid ST1926 by the histone deacetylase inhibitor, RC307: enhanced DNA damage response.
   Int J Cancer, 126(5): 1246-55. [Abstract] [Full-text]
9. Potentiation of temozolomide cytotoxicity by inhibition of DNA polymerase beta is accentuated by BRCA2 mutation.
   Cancer Res, 70(1): 409-17. [Abstract] [Full-text]
10. Enzyme-replacement therapy in a 5-month-old boy with attenuated presymptomatic MPS I: 5-year follow-up.
    Pediatrics, 125(1): e183-7. [Abstract] [Full-text]
11. Choline PET for monitoring early tumor response to photodynamic therapy.
    J Nucl Med, 51(1): 130-8. [Abstract] [Full-text]
12. Intravitreal crystalline drug delivery for intraocular proliferation diseases.
    Invest Ophthalmol Vis Sci, 51(1): 474-81. [Abstract] [Full-text]
13. Mechanisms of corneal tissue cross-linking in response to treatment with topical riboflavin and long-wavelength ultraviolet radiation (UVA).
    Invest Ophthalmol Vis Sci, 51(1): 129-38. [Abstract] [Full-text]
14. Adoptive transfer of cytomegalovirus/Epstein-Barr virus-specific immune effector cells for therapeutic and preventive/preemptive treatment of pediatric allogeneic cell transplant recipients.
    J Pediatr Hematol Oncol, 32(1): e31-7. [Abstract] [Full-text]
15. Epstein Barré virus-negative diffuse large B-cell lymphoma in an HIV-infected man with a durable complete remission on highly active antiretroviral therapy alone.
    South Med J, 103(1): 76-80. [Abstract] [Full-text]
16. PTEN status in advanced colorectal cancer treated with cetuximab.
    Br J Cancer, 102(1): 162-4. [Abstract] [Full-text]
17. Metabolic assessment of the action of targeted cancer therapeutics using magnetic resonance spectroscopy.
    Br J Cancer, 102(1): 1-7. [Abstract] [Full-text]
18. Quality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancer.
    Br J Cancer, 102(1): 59-67. [Abstract] [Full-text]
19. A quality-adjusted survival analysis (Q-TWiST) of rituximab plus CVP vs CVP alone in first-line treatment of advanced follicular non-Hodgkin's lymphoma.
    Br J Cancer, 102(1): 19-22. [Abstract] [Full-text]
20. Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib.
    Br J Cancer, 102(1): 80-6. [Abstract] [Full-text]
21. Assessment of residual tumour by FDG-PET: conventional imaging and clinical examination following primary chemotherapy of large and locally advanced breast cancer.
    Br J Cancer, 102(1): 35-41. [Abstract] [Full-text]
22. Impending paradoxical embolism: systematic review of prognostic factors and treatment.
    Chest, 137(1): 164-70. [Abstract] [Full-text]
23. Nrf2: friend or foe for chemoprevention?
    Carcinogenesis, 31(1): 90-9. [Abstract] [Full-text]
24. The vulnerability of the heart as a pluricellular paracrine organ: lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy.
    Circ Res, 106(1): 35-46. [Abstract] [Full-text]
25. Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics.
    Circ Res, 106(1): 21-34. [Abstract] [Full-text]
26. Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer.
    J Clin Oncol, 28(2): 193-201. [Abstract] [Full-text]
27. Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM).
    Blood, 115(1): 32-7. [Abstract] [Full-text]
28. Porphyrin-cyclodextrin conjugates as a nanosystem for versatile drug delivery and multimodal cancer therapy.
    J Med Chem, 53(1): 128-38. [Abstract] [Full-text]
29. Subconjunctival delivery of antibiotics in a controlled-release system: a novel anti-infective prophylaxis approach for cataract surgery.
    Arch Ophthalmol, 128(1): 81-7. [Abstract] [Full-text]
30. Preparation, characterization and in silico modeling of biodegradable nanoparticles containing cyclosporine A and coenzyme Q10.
    Nanotechnology, 21(6): 065104. [Abstract] [Full-text]
31. Delivery of paclitaxel by physically loading onto poly(ethylene glycol) (PEG)-graft-carbon nanotubes for potent cancer therapeutics.
    Nanotechnology, 21(6): 065101. [Abstract] [Full-text]
32. Primary chemotherapy for intracranial germ cell tumors: results of the third international CNS germ cell tumor study.
    Pediatr Blood Cancer, 54(3): 377-83. [Abstract] [Full-text]
33. Trilateral retinoblastoma: potentially curable with intensive chemotherapy.
    Pediatr Blood Cancer, 54(3): 384-7. [Abstract] [Full-text]
34. Inflammatory myofibroblastic tumor of the conjunctiva: response to chemotherapy with low-dose methotrexate and vinorelbine.
    Pediatr Blood Cancer, 54(3): 483-5. [Abstract] [Full-text]
35. Long-term cardiac follow-up of children treated with anthracycline doses of 300 mg/m2 or less for acute lymphoblastic leukemia.
    Pediatr Blood Cancer, 54(3): 444-8. [Abstract] [Full-text]
36. High-grade acute organ toxicity during preoperative radiochemotherapy as positive predictor for complete histopathologic tumor regression in multimodal treatment of locally advanced rectal cancer.
    Strahlenther Onkol, 186(1): 30-5. [Abstract] [Full-text]
37. Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders.
    J Clin Oncol, 28(3): 418-23. [Abstract] [Full-text]
38. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance.
    J Clin Oncol, 28(3): 453-9. [Abstract] [Full-text]
39. Perioperative crystalloid and colloid fluid management in children: where are we and how did we get here?
    Anesth Analg, 110(2): 375-90. [Abstract] [Full-text]
40. Intraosseous infusions: a review for the anesthesiologist with a focus on pediatric use.
    Anesth Analg, 110(2): 391-401. [Abstract] [Full-text]
41. Drug dispensing errors in a ward stock system.
    Basic Clin Pharmacol Toxicol, 106(2): 100-5. [Abstract] [Full-text]
42. Desferrioxamine shows different potentials for enhancing 5-aminolaevulinic acid-based photodynamic therapy in several cutaneous cell lines.
    Lasers Med Sci, 25(2): 251-7. [Abstract] [Full-text]
43. Toluidine blue-mediated photodynamic therapy of oral wound infections in rats.
    Lasers Med Sci, 25(2): 233-8. [Abstract] [Full-text]
44. Effect of photodynamic therapy on the healing of cutaneous third-degree-burn: histological study in rats.
    Lasers Med Sci, 25(2): 221-8. [Abstract] [Full-text]
45. Endothelial nitric oxide synthase gene variants and primary open-angle glaucoma: interactions with sex and postmenopausal hormone use.
    Invest Ophthalmol Vis Sci, 51(2): 971-9. [Abstract] [Full-text]
46. A modular Phase I study of lenalidomide and paclitaxel in metastatic castration-resistant prostate cancer following prior taxane therapy.
    Cancer Chemother Pharmacol, 65(4): 811-5. [Abstract] [Full-text]
47. Identification of dynamin-2-mediated endocytosis as a new target of osteoporosis drugs, bisphosphonates.
    Mol Pharmacol, 77(2): 262-9. [Abstract] [Full-text]
48. Progression and treatment of HER2-positive breast cancer.
    Cancer Chemother Pharmacol, 65(4): 611-23. [Abstract] [Full-text]
49. Defining patient outcomes in stage IV colorectal cancer: a prospective study with baseline stratification according to disease resectability status.
    Br J Cancer, 102(2): 255-61. [Abstract] [Full-text]
50. CD133+ circulating haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients.
    Br J Cancer, 102(2): 268-75. [Abstract] [Full-text]
51. Reinforcing effects of sigma-receptor agonists in rats trained to self-administer cocaine.
    J Pharmacol Exp Ther, 332(2): 515-24. [Abstract] [Full-text]
52. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
    Cancer Chemother Pharmacol, 65(4): 755-63. [Abstract] [Full-text]
53. Gemcitabine and oxaliplatin in patients with unresectable biliary cancer including gall bladder cancer: a Korean Cancer Study Group phase II trial.
    Cancer Chemother Pharmacol, 65(4): 641-7. [Abstract] [Full-text]
54. Impact of infusion speed on the safety and effectiveness of prothrombin complex concentrate: a prospective clinical trial of emergency anticoagulation reversal.
    Ann Hematol, 89(3): 309-16. [Abstract] [Full-text]
55. Dose-dense therapy improves survival in aggressive non-Hodgkin's lymphoma.
    Ann Hematol, 89(3): 273-82. [Abstract] [Full-text]
56. Systematic analysis of public domain compound potency data identifies selective molecular scaffolds across druggable target families.
    J Med Chem, 53(2): 752-8. [Abstract] [Full-text]
57. Synthesis and preliminary biological evaluation of high-drug-load paclitaxel-antibody conjugates for tumor-targeted chemotherapy.
    J Med Chem, 53(2): 586-94. [Abstract] [Full-text]
58. Enhancing the intestinal absorption of molecules containing the polar guanidino functionality: a double-targeted prodrug approach.
    J Med Chem, 53(2): 624-32. [Abstract] [Full-text]
59. Points to consider when establishing drug product specifications for parenteral microspheres.
    AAPS J, 12(1): 27-32. [Abstract] [Full-text]
60. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study.
    Arterioscler Thromb Vasc Biol, 30(2): 340-5. [Abstract] [Full-text]
61. Zinc phthalocyanine-loaded PLGA biodegradable nanoparticles for photodynamic therapy in tumor-bearing mice.
    Lasers Med Sci, 25(2): 283-72. [Abstract] [Full-text]
62. Intra-brain microinjection of human mesenchymal stem cells decreases allodynia in neuropathic mice.
    Cell Mol Life Sci, 67(4): 655-69. [Abstract] [Full-text]
63. Targeting the cancer kinome through polypharmacology.
    Nat Rev Cancer, 10(2): 130-7. [Abstract] [Full-text]
64. Scalable fluidic injector arrays for viral targeting of intact 3-D brain circuits.
    J Vis Exp. [Abstract] [Full-text]
65. Mass reduction by radiofrequency ablation before hepatic arterial infusion chemotherapy improved prognosis for patients with huge hepatocellular carcinoma and portal vein thrombus.
    AJR Am J Roentgenol, 194(2): W221-6. [Abstract] [Full-text]
66. Porous metal-organic-framework nanoscale carriers as a potential platform for drug delivery and imaging.
    Nat Mater, 9(2): 172-8. [Abstract] [Full-text]
67. A recombinant adenovirus type 35 fiber knob protein sensitizes lymphoma cells to rituximab therapy.
    Blood, 115(3): 592-600. [Abstract] [Full-text]
68. Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.
    Blood, 115(3): 489-95. [Abstract] [Full-text]
69. Vinorelbine and fluorouracil plus leucovorin combination (ViFL) in patients with anthracycline and taxane-pretreated metastatic breast cancer: a phase II study.
    J Cancer Res Clin Oncol, 136(3): 411-7. [Abstract] [Full-text]
70. Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases.
    J Cancer Res Clin Oncol, 136(3): 371-8. [Abstract] [Full-text]
71. Evaluation of the cost-effectiveness of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (peritonectomy) at the St George Hospital peritoneal surface malignancy program.
    Ann Surg, 251(2): 323-9. [Abstract] [Full-text]
72. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
    Ann Surg, 251(2): 254-60. [Abstract] [Full-text]
73. Sociodemographic differences in antiepileptic drug prescriptions to adult epilepsy patients.
    Neurology, 74(4): 295-301. [Abstract] [Full-text]
74. Primary esophageal carcinoma in the era of highly active antiretroviral therapy.
    Arch Intern Med, 170(2): 203-7. [Abstract] [Full-text]
75. Persistent use of secondary preventive drugs declines rapidly during the first 2 years after stroke.
    Stroke, 41(2): 397-401. [Abstract] [Full-text]
76. The benefits of intravenous thrombolysis relate to the site of baseline arterial occlusion in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET).
    Stroke, 41(2): 295-9. [Abstract] [Full-text]
77. Assessment and improvement of figures to visually convey benefit and risk of stroke thrombolysis.
    Stroke, 41(2): 300-6. [Abstract] [Full-text]
78. Safety and efficacy of ultrasound-enhanced thrombolysis: a comprehensive review and meta-analysis of randomized and nonrandomized studies.
    Stroke, 41(2): 280-7. [Abstract] [Full-text]
79. Low-dose weekly platinum-based chemoradiation for advanced head and neck cancer.
    Laryngoscope, 120(2): 236-42. [Abstract] [Full-text]
80. Sustained delivery of lidocaine into the cochlea using poly lactic/glycolic acid microparticles.
    Laryngoscope, 120(2): 377-83. [Abstract] [Full-text]
81. Standard-fluence versus low-fluence photodynamic therapy in chronic central serous chorioretinopathy: a nonrandomized clinical trial.
    Am J Ophthalmol, 149(2): 307-315.e2. [Abstract] [Full-text]
82. Two-year visual results for older Asian women treated with photodynamic therapy or bevacizumab for myopic choroidal neovascularization.
    Am J Ophthalmol, 149(1): 140-6. [Abstract] [Full-text]
83. Prevention of mother-to-child transmission of HIV-1 using highly active antiretroviral therapy in rural Yunnan, China.
    J Acquir Immune Defic Syndr, 53: S15-22. [Abstract] [Full-text]
84. Incident depression symptoms are associated with poorer HAART adherence: a longitudinal analysis from the Nutrition for Healthy Living study.
    J Acquir Immune Defic Syndr, 53(2): 266-72. [Abstract] [Full-text]
85. Medication reconciliation and hypertension control.
    Am J Med, 123(2): 182.e9-182.e15. [Abstract] [Full-text]
86. Vitamin E and rutin synergistically inhibit expression of vascular endothelial growth factor through down-regulation of binding activity of activator protein-1 in human promyelocytic leukemia (HL-60) cells.
    Chem Biol Interact, 183(3): 434-41. [Abstract] [Full-text]
87. Periocular ulcerative dermatitis associated with gentamicin ointment prophylaxis in newborns.
    J Pediatr, 156(2): 320-1. [Abstract] [Full-text]
88. Prevention of hyponatremia during maintenance intravenous fluid administration: a prospective randomized study of fluid type versus fluid rate.
    J Pediatr, 156(2): 313-9.e1-2. [Abstract] [Full-text]
89. Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074).
    Gynecol Oncol, 116(2): 157-62. [Abstract] [Full-text]
90. The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade.
    Gynecol Oncol, 116(2): 222-33. [Abstract] [Full-text]
91. Maintenance immunotherapy in recurrent ovarian cancer: long term follow-up of a phase II study.
    Gynecol Oncol, 116(2): 202-7. [Abstract] [Full-text]
92. Prevalence and clinical relevance of pathological hepatic changes occurring after neoadjuvant chemotherapy for colorectal liver metastases.
    Surgery, 147(2): 185-94. [Abstract] [Full-text]
93. Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial.
    J Clin Oncol, 28(4): 586-95. [Abstract] [Full-text]
94. Adverse events among the elderly receiving chemotherapy for advanced non-small-cell lung cancer.
    J Clin Oncol, 28(4): 620-7. [Abstract] [Full-text]
95. Long-term follow-up of Cisplatin combination chemotherapy in patients with disseminated nonseminomatous germ cell tumors: is a postchemotherapy retroperitoneal lymph node dissection needed after complete remission?
    J Clin Oncol, 28(4): 531-6. [Abstract] [Full-text]
96. Management of disseminated nonseminomatous germ cell tumors with risk-based chemotherapy followed by response-guided postchemotherapy surgery.
    J Clin Oncol, 28(4): 537-42. [Abstract] [Full-text]
97. Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer.
    J Clin Oncol, 28(4): 628-33. [Abstract] [Full-text]
98. Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426.
    J Clin Oncol, 28(4): 614-9. [Abstract] [Full-text]

© 2004-2012 Chemotherapy Research Today. All Rights Reserved.